NUC-7738 is under clinical development by NuCana and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect NUC-7738’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NUC-7738 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

NUC-7738 overview

NUC-7738 is under development for the treatment of solid tumors including metastatic cutaneous melanoma, metastatic lung adenocarcinoma,  B-NHL, Hodgkin's lymphoma, T-cell lymphomas and lymphoma. It is a protide transformation of cordycepin. It acts by targeting adenosine monophosphate activated protein kinase (AMPK). The drug candidate is developed based on ProTide technology.

NuCana overview

NuCana, formerly NuCana BioMed, is a clinical-stage biopharmaceutical company. It focuses on developing novel and transformational medicines for cancer treatments. Its key products include Acelarin, which is in phase III clinical studies, and used to treat biliary tract cancer. The company is also developing products such as NUC-3373 and NUC-7738, which are under Phase I study and used to treat solid tumors. NuCana develops products based on the ProTide technology platform, which focuses on developing new generation, anti-cancer agents. The company markets its products in the UK and the US. NuCana is headquartered in Edinburgh, the UK.

Quick View NUC-7738 LOA Data

Report Segments
  • Innovator
Drug Name
  • NUC-7738
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.